Table 4

Tissue immune correlatives

SubgroupTissue siteTPSPD-L1 H-scoreMPSTIL score (0–3)Stromal interfaceBest response
Clinical benefit (CR, PR or SD >6 months)
HR+Bladder30130702NoSD >6 months
HR+Liver97331NoPR
HR+Adrenal100001NoPR
TNBreast100002YesSD >6 months
No clinical benefit (PD or SD <6 months)
HR+Lymph node100003YesPD
HR+Skin100000NoPD
HR+Lung100002NoSD
HR+Liver100001NoSD
HR+Liver100001NoSD
HR+Liver100001YesPD
HR+Liver98222NoPD
TNLiver951153YesSD
TNLung100001YesPD
TNLiver10210903NoPD
TNSkin98221NoPD
  • TPS=% of PD-L1-positive (IHC >1+) tumor cells; PD-L1 H-score=(% IHC 1+×1)+(% IHC 2+×2)+(% IHC 3+×3); MPS–TPS with mononuclear inflammatory cells expressing PD-L1 also included.

  • .CR, complete response; HR+, hormone receptor-positive endocrine-refractory; IHC, immunohistochemistry; MPS, modified proportion score; PD, progressive disease ; PD-L1, programmed death-ligand 1 ; PR, partial response ; SD, stable disease ; TN, triple negative; TPS, tumor proportion score.